Elefante Mark B Has $5.90 Million Position in Eli Lilly and Company $LLY

Elefante Mark B boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 22.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,921 shares of the company’s stock after purchasing an additional 890 shares during the quarter. Eli Lilly and Company comprises 2.5% of Elefante Mark B’s portfolio, making the stock its 15th largest holding. Elefante Mark B’s holdings in Eli Lilly and Company were worth $5,902,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Benchmark Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 3.0% in the second quarter. Benchmark Investment Advisors LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after purchasing an additional 62 shares during the period. LM Advisors LLC lifted its stake in shares of Eli Lilly and Company by 20.4% in the second quarter. LM Advisors LLC now owns 5,649 shares of the company’s stock worth $6,791,000 after buying an additional 957 shares during the last quarter. Clear Harbor Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 128.3% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 4,602 shares of the company’s stock worth $5,520,000 after buying an additional 2,586 shares during the period. Kirtland Hills Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Kirtland Hills Capital Management LLC now owns 425 shares of the company’s stock worth $510,000 after buying an additional 27 shares during the period. Finally, Vista Investment Management grew its stake in Eli Lilly and Company by 14.4% in the 2nd quarter. Vista Investment Management now owns 398 shares of the company’s stock valued at $477,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research report on Friday, August 7th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Down 0.6%

Shares of LLY stock opened at $1,168.98 on Friday. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 39.23, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The firm’s fifty day simple moving average is $1,189.22 and its 200 day simple moving average is $1,065.30. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.S. FDA approved Mounjaro (tirzepatide) to reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in high-risk adults with Type 2 diabetes. The expanded label gives Lilly access to a broader diabetes and cardiovascular market and strengthens Mounjaro’s competitive position. US FDA approves Lilly’s Mounjaro to reduce cardiovascular risk
• Positive Sentiment: The approval is supported by clinical data showing Mounjaro produced an 8% lower rate of major cardiovascular events than Lilly’s Trulicity, potentially making the drug more attractive to physicians, patients and payers. Mounjaro versus Trulicity
• Positive Sentiment: The decision expands the commercial opportunity for Lilly’s approximately $9.94 billion Mounjaro franchise beyond blood-sugar control and weight loss, potentially supporting long-term revenue growth. Lilly’s Mounjaro franchise wins a heart-risk label
• Positive Sentiment: Lilly’s oncology business and pipeline are providing additional diversification, with oncology revenue reportedly rising 11% in the first half of 2026. Can Lilly’s oncology portfolio drive growth beyond GLP-1 drugs?
• Neutral Sentiment: Employer coverage for GLP-1 weight-loss medicines reportedly fell from 72% to 60%, raising concerns about affordability and future demand. However, Lilly’s recent 47% revenue growth suggests volume remains resilient despite payer pressure. GLP-1 coverage and Lilly’s weight-loss boom
• Negative Sentiment: LLY has pulled back after reaching a record high, while healthcare stocks broadly declined. Profit-taking and the stock’s elevated valuation may be limiting the immediate reaction to the positive Mounjaro news. Eli Lilly stock pulls back after hitting record high

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last three months. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.